Subtype
Primary Malignant Liver Neoplasm
CI-CAN-00006507Explore in graph →
807 active trials14 approved drugs17 evidence items
- NCIt
- C34803
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006507Explore in graph →
Clinical trials
3,489 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (403)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT00913757 | A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area | completed | — | 1,871 | National Cancer Institute (NCI)NIH | 1 | May 4, 2020 | clinicaltrials |
| NCT02834546 | Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma(ACTES) | completed | — | 143 | University Hospital, BordeauxOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT01775501 | Sorafenib + mFOLFOX for Hepatocellular Carcinoma | completed | Phase 2 | 40 | Massachusetts General HospitalOTHER | 1 | Apr 22, 2020 | clinicaltrials |
| NCT02716766 | Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | completed | Phase 2 | 46 | The University of Hong KongOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03578874 | SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | completed | Phase 2 | 15 | The University of Hong KongOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT03806218 | Bipolar RFA Using Twin ICW Electrodes vs. Switching Monopolar RFA for Recurrent HCC | completed | N/A | 77 | Seoul National University HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT03594188 | Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy | completed | N/A | 24 | RenJi HospitalOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02358070 | Epidemiologic Study of Hepatocellular Carcinoma in the US | completed | — | 45 | Stanford UniversityOTHER | 1 | Mar 24, 2020 | clinicaltrials |
| NCT03699657 | Dual and Single Switching Monopolar RFA Using Separable Clustered Electrode for Treatment of HCC | completed | N/A | 86 | Seoul National University HospitalOTHER | 1 | Mar 20, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01347333 | Stereotactic Body Radiotherapy for Liver Tumors | completed | N/A | 23 | Mercy ResearchOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT04266548 | Arterial Base Fluorescence Segmental Positive Staining | completed | N/A | 8 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2020 | clinicaltrials |
| NCT01833299 | Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma | completed | Phase 3 | 120 | Sun Yat-sen UniversityOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02240433 | A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT03203005 | IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients | completed | Phase 1 / Phase 2 | 22 | National Cancer Institute, NaplesOTHER | 5 | Feb 5, 2020 | clinicaltrials |
| NCT03804593 | HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) | completed | — | 175 | Epigenomics, IncINDUSTRY | 1 | Jan 30, 2020 | clinicaltrials |
| NCT00040846 | Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies | completed | Phase 2 | 60 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 29, 2020 | clinicaltrials |
| NCT02548780 | LifePearl-Doxo Pharmacokinetic (PK) Study | completed | N/A | 15 | Terumo Europe N.V.INDUSTRY | 3 | Jan 27, 2020 | clinicaltrials |
| NCT03053596 | LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry) | completed | — | 102 | Terumo Europe N.V.INDUSTRY | 2 | Jan 27, 2020 | clinicaltrials |
| NCT02409524 | An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects | completed | Phase 2 | 15 | Mirror Biologics, Inc.INDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT00006251 | Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer | completed | Phase 1 / Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Jan 21, 2020 | clinicaltrials |
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 18, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT00341705 | The Second Multicenter Hemophilia Cohort Study | completed | — | 2,565 | National Cancer Institute (NCI)NIH | 8 | Dec 17, 2019 | clinicaltrials |
| NCT00825877 | Long-term Follow-up of HALT-C Sustained Virological Responders | completed | — | 140 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT02730611 | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma(METSLIVER) | completed | — | 124 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT01334112 | Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma(AXITINIB) | completed | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT01853618 | Tremelimumab With Chemoembolization or Ablation for Liver Cancer | completed | Phase 1 / Phase 2 | 61 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02774187 | Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | completed | Phase 3 | 247 | Sun Yat-sen UniversityOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00908752 | Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC(BRISK TA) | completed | Phase 3 | 734 | Bristol-Myers SquibbINDUSTRY | 13 | Dec 2, 2019 | clinicaltrials |
| NCT02643173 | Hepatocellular Carcinoma Recurrence and Anesthesia | completed | — | 259 | Seoul National University Bundang HospitalOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT04172194 | Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas | completed | — | 64 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT04161911 | A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy | completed | — | 1,426 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02259647 | Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma | completed | N/A | 60 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 28, 2019 | clinicaltrials |
| NCT03162198 | Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | completed | — | 53 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Oct 23, 2019 | clinicaltrials |
| NCT00844454 | Multi-pronged Ethanol Ablation and Radiofrequency Ablation of Early-stage Hepatocellular Carcinoma(QPEAvsRFA) | completed | N/A | 81 | Sun Yat-sen UniversityOTHER | 1 | Oct 8, 2019 | clinicaltrials |
| NCT02387307 | A Study of rSIFN-co in Subjects With Advanced Solid Tumors(rSIFN-01) | completed | Phase 1 | 42 | Sichuan Huiyang Life Science and Technology CorporationINDUSTRY | 1 | Sep 27, 2019 | clinicaltrials |
| NCT02854839 | A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma | completed | Phase 2 | 78 | GC Cell CorporationINDUSTRY | 1 | Sep 26, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02814461 | The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC | completed | Phase 1 | 9 | Shin Kong Wu Ho-Su Memorial HospitalOTHER | 1 | Sep 23, 2019 | clinicaltrials |
| NCT01850368 | Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion | completed | Phase 2 | 35 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT01850667 | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma | completed | Phase 2 | 74 | Korea Cancer Center HospitalOTHER | 1 | Sep 20, 2019 | clinicaltrials |
| NCT04072250 | Surgery for Recurrent Intrahepatic Cholangiocarcinoma | completed | — | 216 | Chang Gung Memorial HospitalOTHER | 1 | Sep 13, 2019 | clinicaltrials |
Data updated 24 days agoSource updated May 13, 2020source: clinicaltrials